Comparison of 18F Fluoride PET/CT and 99mTc-MDP Bone Scan in the Detection of Skeletal Metastases in Urinary Bladder Carcinoma
Comparison of 18F Fluoride PET/CT and 99mTc-MDP Bone Scan in the Detection of Skeletal Metastases in Urinary Bladder Carcinoma
复制标题
DOI:
10.1097/rlu.0b013e31828da5cc
复制
发表时间:
2013-08-01
影响因子:
10.6
通讯作者:
Mittal, Bhagwant Rai
中科院分区:
文献类型:
--
作者:
Chakraborty, Dhritiman;Bhattacharya, Anish;Mittal, Bhagwant Rai
Aim: The aim of this study was to compare F-18-fluoride PET/CT and Tc-99m-MDP bone scintigraphy in the detection of skeletal metastases in urinary bladder carcinoma.Patients and Methods: In this prospective study, 48 patients with urinary bladder carcinoma (44 male and 4 female patients, aged 35-80 years) underwent Tc-99m-MDP planar and SPECT/CT bone scan (BS) followed by F-18-fluoride PET/CT within 48 hours. Skeletal metastasis diagnosed on each of these techniques was compared against a final diagnosis based on contrast-enhanced CT, MRI, skeletal survey, clinical follow-up, and histological correlation.Results: F-18-fluoride PET/CT identified bony metastases and changed the management in 17 of 48 patients (35%). The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of Tc-99m-MDP planar BS were 82.35%, 64.51%, 56%, 86.95%, and 70.83%; of Tc-99m-MDP SPECT/CT were 88.23%, 74.19%, 65.21%, 92%, and 79.16%; and of F-18-fluoride PET/CT were 100%, 87.09%, 80.95%, 100%, and 91.66%, respectively. Fair agreement between Tc-99m-MDP planar BS and F-18-fluoride PET/CT (kappa = 0.42) and excellent agreement between SPECT/CT and F-18-fluoride PET/CT (kappa = 0.74) were found.Conclusions: F-18-fluoride PET/CT has higher sensitivity, specificity, positive predictive value, negative predictive value, and accuracy in detecting bone metastases in urinary bladder carcinoma than conventional Tc-99m-MDP planar BS. SPECT/CT improves all these parameters compared with planar BS and may serve as a cost-effective screening procedure for the detection of skeletal metastases in high-risk patients.